PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro. PepGen on Wednesday ...
PepGen Inc. is a Boston-based clinical-stage biopharmaceutical concern focused on the development of oligonucleotide therapies for the treatment of severe neuromuscular and neurologic diseases. It's ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
PepGen (PEPG) shares fell ~44% in after-hours trading after the Massachusetts-based biotech company shared results from a mid-stage trial for its main treatment, PGN-EDODM1, which is aimed at myotonic ...
PepGen’s PEPG shares were down almost 16.3% on May 30, after market hours. This happened soon after the company announced that it received a clinical hold notice from the FDA regarding PEPG’s ...
・PEPG fell after its Phase 2 Freedom 2 study showed no meaningful improvements in walking speed or hand strength at the starting dose of 5 mg/kg. ・SGMO slipped after reporting a Q4 loss per share of ...
On Tuesday, PepGen Inc. (NASDAQ:PEPG) announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results